Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Modell

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Pharmacopsychiatry|January 5, 2002
Current scientific programmes in German neurosciences: supported by official sponsorsS Modell, F Holsboer
Pharmacopsychiatry|March 1, 1996
Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range studyS Modell, D Naber, R Holzbach
Psychopathology|January 1, 1996
Dysmorphophobia: differential-diagnostic aspectsS Modell, G Kurtz, P Hoff
Der Nervenarzt|May 1, 1993
[Paranoid psychosis in a patient with hypothyroidism and vitamin B12 deficiency]S Modell, D Naber, F Müller-Spahn
Der Nervenarzt|July 1, 1992
[New aspects in the diagnosis, pathogenesis and therapy of schizophrenic negative symptoms]F Müller-Spahn, S Modell, M Thomma
Neuroendocrinology|March 1, 1997
Corticosteroid receptor function is decreased in depressed patientsS Modell, A Yassouridis, J Huber, et al.
Journal of Psychiatric Research|October 27, 2004
The Munich vulnerability study on affective disorders: premorbid neuroendocrine profile of affected high-risk probandsM Ising, C J Lauer, F Holsboer, et al.
Acta Psychiatrica Scandinavica|March 31, 2004
The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individualsM Ising, C J Lauer, F Holsboer, et al.
Der Nervenarzt|October 1, 1994
[Rhabdomyolysis in neuroleptic therapy: an abortive malignant neuroleptic syndrome?]O Peschel, G Kurtz, W Müller-Felber, et al.
Pharmacopsychiatry|March 2, 2006
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophreniaG Gründer, M Kungel, M Ebrecht, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Pharmacopsychiatry|January 5, 2002
Current scientific programmes in German neurosciences: supported by official sponsorsS Modell, F Holsboer
Pharmacopsychiatry|March 1, 1996
Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range studyS Modell, D Naber, R Holzbach
Psychopathology|January 1, 1996
Dysmorphophobia: differential-diagnostic aspectsS Modell, G Kurtz, P Hoff
Der Nervenarzt|May 1, 1993
[Paranoid psychosis in a patient with hypothyroidism and vitamin B12 deficiency]S Modell, D Naber, F Müller-Spahn
Der Nervenarzt|July 1, 1992
[New aspects in the diagnosis, pathogenesis and therapy of schizophrenic negative symptoms]F Müller-Spahn, S Modell, M Thomma
Neuroendocrinology|March 1, 1997
Corticosteroid receptor function is decreased in depressed patientsS Modell, A Yassouridis, J Huber, et al.
Journal of Psychiatric Research|October 27, 2004
The Munich vulnerability study on affective disorders: premorbid neuroendocrine profile of affected high-risk probandsM Ising, C J Lauer, F Holsboer, et al.
Acta Psychiatrica Scandinavica|March 31, 2004
The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individualsM Ising, C J Lauer, F Holsboer, et al.
Der Nervenarzt|October 1, 1994
[Rhabdomyolysis in neuroleptic therapy: an abortive malignant neuroleptic syndrome?]O Peschel, G Kurtz, W Müller-Felber, et al.
Pharmacopsychiatry|March 2, 2006
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophreniaG Gründer, M Kungel, M Ebrecht, et al.
Pageof 3